NDATOPICALCREAM
Approved
Jul 2025
Lifecycle
Growth
Competitive Pressure
0/100
Clinical Trials
18
Data completeness
5/8 — Partial
ANZUPGO (delgocitinib) by Leo Pharma is janus kinase inhibitors [moa]. First approved in 2025.
Drug data last refreshed 22h ago · AI intelligence enriched Yesterday
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ANZUPGO (delgocitinib) is a topical Janus Kinase inhibitor cream approved by the FDA on July 23, 2025, for dermatological indications. It works by inhibiting JAK signaling to reduce inflammatory skin responses. The drug represents a novel topical approach to JAK inhibition in dermatology.
Growth5.0 years to LOE
Early-stage growth product with no current competitive pressure, suggesting opportunity for market expansion and team scaling in the coming years.
Mechanism of Action
Janus Kinase Inhibitors
Pharmacologic Class:
Janus Kinase Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (18)
Safety and Biomarker Responses of Delgocitinib (JAK1,2,3/TYK2 Inhibitor) in Central Centrifugal Cicatricial Alopecia and Lichen Planopilaris
Started May 2026
30 enrolled
Central Centrifugal Cicatricial AlopeciaLichen Planopilaris
A 52-Week Trial to Investigate the Efficacy and Safety of Delgocitinib Cream in Adult Participants With Lichen Sclerosus
Started May 2026
652 enrolled
Lichen Sclerosus
A 16-week Trial to Investigate the Efficacy and Safety of Delgocitinib Cream 20 mg/g in Adult Participants With Mild to Severe Palmoplantar Pustulosis
Started Sep 2025
135 enrolled
Palmoplantar Pustulosis
Real-World Evidence: Effectiveness and Safety of Chronic Hand Eczema Treatment With Delgocitinib Cream
Started Jun 2025
1,000 enrolled
Chronic Hand Eczema (CHE)
A Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of Delgocitinib Cream in Chinese Adults and Adolescents With Moderate to Severe Chronic Hand Eczema
Started Sep 2023
362 enrolled
Chronic Hand Eczema
Worked on ANZUPGO at Leo Pharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.